Wesentliche Daten zur multimodalen Therapie der Peritonealkarzinose

Einschluss und Ausschlusskriterien im Vorfeld zur multimodalen Therapie der Peritonealkarzinose

include – exclude

Discuss in tumor board

Tumortype

Appendiceal tumor

in

Colorectal cancer

in

Gastric cancer primary

in

Gastric cancer recurrent

ex

Pancreatic cancer

ex

Ovarian cancer recurrent

in

Ovarian cancer primary

discuss

Primary peritoneal carcinoma

in

Peritoneal mesothelioma

in

Rare primary or secondary tumours of the peritoneum

discuss

Tumorstage

Mesenteric and/or paraaortal lymph node involvement

ex

Extraabdominal metastases

ex

Liver metastases

ex

discuss for colorectal cancer

Clinical parameters

Ileus

ex

Renal insufficiency

ex

More than 2 previous therapeutic approaches

discuss

Age > 70

discuss

Pulmonary and cardiovascular disorders

discuss (plus anaesthesiologist and internal specialist)

 

Survival rate of subgroups of patients with positive prognostic factors after CRS and IPHC /EPIC

Primary tumour

Selection criteria

Survival rate
at %

Author

Gastric

Limited extent of PC (P1)

8 yrs

55 %

Fujimoto

Gastric

Optimal CRS

2 yrs

45 %

Hall

Colorectal

Limited PC and diffuse PC/ small nodules (<5mm)

Optimal CRS

5 yrs

5yrs

25 %

22%

Glehen

Colorectal

Optimal CRS
Prognostic Score <2,65

5 yrs
3 yrs

43 %
60 %

Verwaal

Colorectal

Optimal CRS

5 yrs

37 %

Shen

Recurrent
Ovarian

Optimal CRS

5 yrs

42 %

Cotte

PC = peritoneal carcinomatosis
CRS = cytoreductive surgery